Pinelopi Gkogkou1, Evangelia Peponi2, Dimitrios Ntaskagiannis2, Samuel Murray3, Asimo Demou4, Ioannis Sainis5, Elli Ioakeim4, Evangelos Briasoulis6, Pericles Tsekeris2. 1. Department of Radiation Oncology, Norfolk and Norwich University Hospital, Norwich, U.K. pinelopi.gkogkou@nnuh.nhs.uk. 2. Department of Radiation Oncology, University Hospital of Ioannina, Ioannina, Greece. 3. Genekor SA, Athens, Greece. 4. Department of Pathology,"Hatzikosta" Community Hospital, Ioannina, Greece. 5. Interscience Molecular Laboratory, Cancer Biobank Center, University of Ioannina, University Campus, Ioannina, Greece. 6. Hematology Department and Interscience Molecular Laboratory, Cancer Biobank Center, University of Ioannina, Ioannina, Greece.
Abstract
BACKGROUND/AIM: The aim of the study was to investigate whether E-cadherin and syndecan-1 are molecular markers of advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: The expression of E-cadherin and syndecan-1 (SDC1) was examined immunohistochemically on tissue specimens of 64 patients, with stage III disease at presentation. The obtained expression data were correlated with clinical parameters. RESULTS: Negative expression of SDC1 was correlated with squamous histology (p=0.002). E-cadherin positive expression was significantly associated with increased 2-year overall survival (OS) rate (p=0.032). In the multivariate Cox analysis, performance status 0-1 was an independent predictor of OS (p=0.001) and disease-free survival (DFS) (p=0.001). E-cadherin expression was an independent predictor of OS (p=0.007) and DFS (p=0.029). CONCLUSION: E-cadherin might be a prognostic factor for OS and DFS in advanced stage NSCLC patients. Further investigations are needed for the establishment of E-cadherin and syndecan-1 as molecular markers, affecting treatment response and survival. Copyright
BACKGROUND/AIM: The aim of the study was to investigate whether E-cadherin and syndecan-1 are molecular markers of advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: The expression of E-cadherin and syndecan-1 (SDC1) was examined immunohistochemically on tissue specimens of 64 patients, with stage III disease at presentation. The obtained expression data were correlated with clinical parameters. RESULTS: Negative expression of SDC1 was correlated with squamous histology (p=0.002). E-cadherin positive expression was significantly associated with increased 2-year overall survival (OS) rate (p=0.032). In the multivariate Cox analysis, performance status 0-1 was an independent predictor of OS (p=0.001) and disease-free survival (DFS) (p=0.001). E-cadherin expression was an independent predictor of OS (p=0.007) and DFS (p=0.029). CONCLUSION:E-cadherin might be a prognostic factor for OS and DFS in advanced stage NSCLCpatients. Further investigations are needed for the establishment of E-cadherin and syndecan-1 as molecular markers, affecting treatment response and survival. Copyright
Authors: Tünde Szatmári; Filip Mundt; Ghazal Heidari-Hamedani; Fang Zong; Elena Ferolla; Andrey Alexeyenko; Anders Hjerpe; Katalin Dobra Journal: PLoS One Date: 2012-10-29 Impact factor: 3.240
Authors: Su Young Kim; Eun Ji Choi; Jeong A Yun; Eun Sun Jung; Seung Taek Oh; Jun Gi Kim; Won Kyung Kang; Sung Hak Lee Journal: Int J Med Sci Date: 2015-01-01 Impact factor: 3.738